Peptide oligomers have detrimental metabolic effects and cause pro-arrhythmic electrophysiological changes in heart atria, suggesting they may contribute to atrial fibrillation.

Vanderbilt research shows that genetic testing in patients with early-onset atrial fibrillation can identify variants associated with more serious cardiomyopathy and arrhythmia syndromes that may otherwise remain undiagnosed.

Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.

Vanderbilt University Medical Center is participating in a trial for a device that could revolutionize the way patients are treated for atrial fibrillation (AF or AFib.)

Postoperative atrial fibrillation (PoAF), a form of arrhythmia, complicates 20-40% of cardiac surgical procedures and 10–20% of non-cardiac thoracic operations, cropping up two to four days after surgery to pose risk of stroke, heart attack, mortality, longer hospital stays and greater cost.

A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.